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Abstract Interleukin-2 (IL-2) regulates the proliferation and
homeostasis of lymphocytes through the coordinated activation
of distinct signaling pathways. Deletion of the acidic-rich domain
of the IL-2 receptor L chain (IL-2RL) prevents association of Src
tyrosine kinases to the receptor, as well as IL-2-induced Akt
activation. Cells bearing this deletion (BafLvA) maintain full
proliferation in response to IL-2 both in vivo and in vitro,
suggesting that those pathways are dispensable for this important
function of IL-2. In this study, we re-examined phosphatidyl-
inositol-3 kinase (PI3K) activation in BafLvA cells and found
that, in BaF/3 IL-2RLvA cells, deletion of the acidic domain
induced constitutive activation of the receptor-associated PI3K
activity. This, in turn, was responsible for the higher basal Akt
activity observed in cells expressing this deletion. Based on these
data, and since pharmacological abrogation of PI3K activity
prevented IL-2-driven cell proliferation of BafLvA cells, we
conclude that the PI3K/Akt pathway is still functionally relevant
in cells bearing this mutation. Moreover, we show that the PI3K-
induced signals are, at least in part, responsible for c-myc
expression. In conclusion, we have used this model to better
identify those signals that are integral components of the
molecular mechanisms responsible for IL-2-regulated cell
proliferation. ß 2001 Published by Elsevier Science B.V. on
behalf of the Federation of European Biochemical Societies.
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1. Introduction
Interleukin-2 (IL-2) is a cytokine essential for the prolifer-
ation of activated T lymphocytes, through its binding to the
heterotrimeric IL-2 receptor (IL-2R) [1]. This receptor is com-
posed of three di¡erent molecules termed K, L and Q. IL-2
binding to the IL-2R induces the rapid heterotrimerization
of the receptor molecules and consequent activation of tyro-
sine kinases of the Jak and Src families [2,3] ; these, in turn,
induce the association/activation of other signaling molecules
to the IL-2R complex. The identi¢cation of the role of the
di¡erent domains in the IL-2RL and Q chains involved in IL-2-
regulated signaling has been made possible by the generation
of cell lines bearing truncations and/or mutations of these
receptor components. Early studies of the IL-2RL subunit
indicated the existence of three distinct and well-de¢ned sub-
domains, conserved in the human and mouse molecules,
which are important for the activation of di¡erent signaling
molecules [4]. The membrane proximal domain of IL-2RL,
also called the S-domain, is essential for IL-2 action and is
responsible for the association of Jak1 kinase [5^7]. The func-
tion of the other two regions seems less essential, since trun-
cations of either domain do not impair IL-2-dependent pro-
liferation [4]. The proline-rich region, also termed the H-
region, contains the tyrosine residues responsible for recruit-
ing Stat 5 and Tat 3 transcription factors [8]. The acidic-rich
domain (A-domain) of IL-2RL comprises amino acids 314^
381 and is responsible for direct association of Src family
tyrosine kinases and Shc [9,10]. Cells expressing receptors
with the A-domain deleted proliferate in response to IL-2,
indicating that direct association of Src family tyrosine ki-
nases is unnecessary for the mitogenic action of IL-2.
IL-2-induced activation of phosphatidylinositol-3 kinase
(PI3K) was demonstrated some time ago [11^13]. As is the
case for other growth factor receptors, generation of 3P phos-
phorylated lipids through PI3K activation is important for the
IL-2-regulated cell cycle, as well as for IL-2 prevention of
apoptosis [14]. The IL-2RL chain is essential for IL-2-induced
PI3K activation [15], but the exact nature of the association/
activation of this lipid kinase following IL-2 binding has not
been fully determined. It has recently been demonstrated that
the IL-2RL chain and Jak1 cooperate functionally in the as-
sociation of the regulatory subunit of p85 [16]. In those stud-
ies, deletion of the A-domain was shown to prevent not only
the phosphorylation on tyrosine residues of p85, but also Akt
activation by IL-2 in cells expressing the deleted receptor.
Proliferation of the cells expressing the A-deleted mutant sug-
gested that IL-2-induced Akt activation was not required for
IL-2 regulation of cell proliferation.
Given the relevance of the PI3K/Akt pathway in the control
of cell proliferation by several mitogens in other systems, we
decided that a more detailed examination was required of the
IL-2 regulation of these pathways in cells expressing the A-
mutant IL-2RL chain. Here we have investigated the conse-
quences of IL-2RL chain A-domain deletion on IL-2 activa-
tion of the PI3K/Akt pathway. Our results indicate that dele-
tion of the A-domain induces higher PI3K activity
constitutively associated to the IL-2RL chain compared to
that associated to wild type IL-2RL. Addition of IL-2 to cells
expressing the mutant receptor diminished this activity, indi-
cating that those mechanisms responsible for downregulation
of this activity remained IL-2-regulated. Constitutive activa-
tion of PI3K induced, in turn, an increase in Akt activity in
cells expressing the mutant receptor. Based on these studies,
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we conclude that deletion of the A-domain in IL-2RL alters
the time course and intensity of PI3K/Akt pathway activation.
Binding of the cytokine to the mutated receptor nonetheless
regulates this important signaling pathway, suggesting that it
is required for the correct delivery of IL-2 proliferative sig-
nals.
2. Materials and methods
2.1. Cells
Murine BaF/3 cells stably transfected with cDNA encoding either
the wild type (BafLwt) or the A-deleted form (BafLvA) of human IL-
2RL have been previously described [4]. Both cell lines were main-
tained in RPMI 1640 medium supplemented with 10% fetal calf se-
rum, L-mercaptoethanol (50 WM), and either 50 U/ml of human re-
combinant IL-2 or 5% WEHI.3B cell-conditioned media and
gentamicin (50 Wg/ml). For analysis of IL-2-induced signals, cells in
exponential growth were washed extensively to remove growth factors
and resuspended in growth factor- and serum-free media (basal me-
dia) for 6 h to induce maximum synchronization. Cells were then
stimulated with IL-2 (50 U/ml) for the times indicated in each experi-
ment. Cell viability of synchronized cells was 95% in all experiments.
2.2. Reagents
Human recombinant IL-2 was from Ho¡mann-La Roche (Nutley,
NJ, USA), wortmannin was from Sigma (St. Louis, MO, USA),
LY294002 was from Biomol Research Labs, Inc. (Plymouth Meeting,
PA, USA). [Q-32P]ATP and the ECL-Plus kit were from Amersham
(Piscataway, NJ, USA). Anti-PI3K(p85), anti-Akt and anti-phospho-
tyrosine horseradish peroxidase (HRPO)-conjugated antibodies were
from Upstate Biotechnology (Lake Placid, NY, USA), anti-human
IL-2RL chain was from Pharmingen (San Diego, CA, USA), anti-
myc was from Oncogene (Boston, MA, USA).
2.3. Plasmids and transfections
The expression cDNA constructs pEF-IL-2RL and pEF-IL-2RLvA
were kindly donated by T. Taniguchi (University of Tokyo, Japan).
Plasmids encoding the constitutively active form of PI3K (p110-
CAAX) and Akt were a gift of J. Downward (ICRF, UK). The c-
myc promoter-driven luciferase gene was a gift from K. Sugamura
(Tohoku University, Japan). For transfection experiments, cells were
electroporated as described [17].
2.4. Analysis of cell growth and apoptosis
The [3H]thymidine incorporation assay was performed as described
[15]. Brie£y, cells were seeded in 96-well plates at an initial concen-
tration of 105 cells/ml. After 16 h, cells were pulsed with 1 WCi of
[3H]thymidine for 6 h prior to harvest. For cell cycle analyses, the
£uorescence of propidium iodide-stained DNA was quantitated on a
per cell basis with an EPIC-XL £ow cyto£uorometer (Coulter, Hia-
leah, FL, USA).
2.5. Immunoprecipitation and immunoblotting
Immunoprecipitation and immunoblotting were carried out as de-
scribed [15]. In brief, after stimulation, cells were washed with ice-cold
phosphate-bu¡ered saline and resuspended in lysis bu¡er (1% Nonidet
P-40 (NP-40), 50 mM Tris^HCl pH 7.4, 150 mM NaCl, 10 mM NaF,
10 mM Na4P2O7, 1 mM Na3VO4, 1 mM PMSF, 10 Wg/ml leupeptin
and 10 Wg/ml aprotinin). Cell lysates were cleared by centrifugation
(12 000 rpm for 15 min) and the supernatants pre-cleared with an
excess of protein Gamma Bind G-Protein Sepharose (Pharmacia).
Pre-cleared lysates were incubated with the indicated antibodies and
the immune complex precipitated with G-protein Sepharose. For c-
myc detection, cells were collected, resuspended in hypotonic bu¡er
(10 mM HEPES pH 7.9, 10 mM KCl, 0.1 mM EDTA, 0.1 mM
EGTA, 2.5 mM dithiothreitol (DTT), 0.6% NP-40 and protease in-
hibitors) and incubated on ice for 15 min. Cell extracts were vortexed
vigorously and centrifuged for 1 min. The supernatants were removed
and ice-cold nuclear extract bu¡er (20 mM HEPES pH 7.9, 25%
glycerol, 0.4 M NaCl, 1 mM EDTA, 1 mM EGTA, 2.5 mM DTT
and protease inhibitors) was added to the pellets. Samples were
rocked (15 min, 4‡C), centrifuged for 5 min and the supernatants
collected. For Western blot analysis, samples were separated by so-
dium dodecyl sulfate^polyacrylamide gel electrophoresis (SDS^
PAGE), then transferred to nitrocellulose membranes (Bio-Rad). Pro-
teins were detected by incubation with the appropriate antibodies
followed by anti-mouse or anti-rabbit HRPO-conjugated antibodies
(Amersham) or G-protein^HRPO conjugate (Bio-Rad). Western blots
were developed using ECL-Plus (Amersham) according to the manu-
facturer’s instructions.
2.6. PI3K assay
The assay of PI3K activity in pellets was performed as described
[12]. Brie£y, immunoprecipitates were washed three times with lysis
bu¡er, once with 0.5 M LiCl and three times with 50 mM Tris^HCl
(pH 7.5), then resuspended in 20 Wl of 50 mM Tris^HCl pH 7.5,
containing PI micelles (Avanti Polar Lipids, Alabaster, AL, USA)
at 0.2 mg/ml. Kinase reaction was initiated by addition of 10 WM
[Q-32P]ATP (10 WCi), 25 WM MgCl2 and 20 WM unlabeled ATP and
allowed to proceed at 25‡C for 10 min. The reaction was terminated
by addition of 100 Wl of 1 M HCl and 200 Wl of a methanol:chloro-
form mixture (1:1 v/v). The extracted phospholipids were resolved by
thin layer chromatography (Silica Gel 60; Merck) on plates coated
with 1% potassium oxalate and developed in chloroform:metha-
nol:4.5 M ammonia (9:7:2 v/v/v), as described [12]. The radioactive
products were visualized by autoradiography and quanti¢ed by scan-
ning laser densitometry.
2.7. Immunoprecipitation and Akt kinase assay
IL-2-stimulated cells were lysed and Akt was immunoprecipitated
with a speci¢c antibody as described [17]. Pellets were washed twice
with lysis bu¡er, twice with high salt bu¡er (0.1 M Tris^HCl pH 8, 0.5
M LiCl, 10 mM MgCl2) and once with kinase bu¡er (50 mM Tris^
HCl pH 7.5, 10 mM MgCl2). The reaction was initiated by addition of
25 Wl of the following mixture: 50 mM Tris^HCl pH 7.5, 10 mM
MgCl2, 1 mM DTT, 25 Wg histone H2B, 1 WM phosphokinase inhib-
itor (Sigma), 50 WM ATP and 5 WCi [Q-32P]ATP. The reaction was
continued for 30 min at 25‡C and terminated by addition of 25 Wl of
Laemmli sample bu¡er. Samples were resolved in SDS^PAGE, and
the radioactive products detected by autoradiography.
2.8. Luciferase assays
BafLwt cells were transfected by electroporation with 30 Wg each of
plasmids encoding a constitutive active form of p110 (p110-CAAX) or
Akt, together with pXLuc and GFP to evaluate the transfection e⁄-
ciency. After 24 h in IL-3-supplemented medium, cells were washed
twice with RPMI 1640 and incubated in basal medium at a ¢nal
concentration of 5U106 cells/ml for 8 h, then lysed and assayed for
luciferase activity. To test the e¡ect of inhibitors, cells were electro-
porated with the pXLuc plasmid and incubated in complete medium
plus or minus IL-2 (50 U/ml) in the presence of the PI3K inhibitor
LY294002 (10 WM). Luciferase activity was determined 18 h after
transfection.
3. Results
3.1. PI3K-speci¢c inhibitors prevent IL-2-dependent
proliferation in BafLwt and BafLvA cells
Our previous experiments and those of other laboratories
indicated that PI3K activation is essential for IL-2-driven pro-
liferation. Nonetheless, it has been shown that deletion of the
A-domain not only abolishes association of Src family tyro-
sine kinases to the receptor, but also prevents IL-2-dependent
activation of the PI3K-regulated serine^threonine kinase Akt
[16]. We thus assessed the role of PI3K-regulated signaling
pathways in IL-2-dependent proliferation by measuring
[3H]thymidine incorporation into cells stably transfected
with the wild type IL-2RL chain (BafLwt) or the A-region
deletion mutant (BafLvA), in the presence of a pharmacolog-
ical inhibitor for this kinase. Treatment with the PI3K inhib-
itor wortmannin diminished proliferation of BafLvA cells to
the same extent (about 50%) as it blocked proliferation of cells
expressing the wild type IL-2RL (Fig. 1).
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3.2. A-domain deletion activates the PI3K/Akt pathway in the
absence of IL-2
Binding of IL-2 to its high a⁄nity receptor is known to
induce the transient activation of PI3K, which can be mea-
sured in immunoprecipitates of the IL-2RL protein. To deter-
mine the e¡ect of the IL-2RL A-domain deletion on receptor-
associated PI3K activity, we performed in vitro PI3K assays
in immunoprecipitated IL-2RL molecules. As predicted, IL-2
increased the PI3K activity measured in immunoprecipitates
of the IL-2RL chain (Fig. 2A). When BafLvA cells were
stimulated with IL-2, there was no apparent increase of IL-
2RL-associated PI3K activity, but rather a decrease with re-
spect to time zero was observed. We examined the lipid kinase
activity associated with the receptor following more prolonged
cell starvation and, surprisingly, found that the receptor-asso-
ciated PI3K activity was higher when starvation time was
increased (Fig. 2B). Consistent with this, in all experiments
using BafLvA cells, IL-2 was found to induce a rapid decrease
of PI3K activity measured in receptor immunoprecipitates.
Akt is a serine^threonine kinase that depends on 3P phosphor-
ylated lipids generation for activation. This protein kinase
thus represents a reliable parameter for determining changes
on PI3K activity. When a phosphorylation assay was per-
formed in anti-Akt immunoprecipitates from BafLwt cells
after IL-2 stimulation, we found, as expected, IL-2-induced
Akt activation (Fig. 2C). No similar e¡ect was detected in
cells expressing the A-deleted mutant. As was the case for
receptor-associated PI3K, basal Akt activity was higher in
cells expressing the A-deletion compared to that of cells ex-
pressing the wild type receptor. This suggests that the higher
basal PI3K activity associated to the A-deleted IL-2RL chain
induces an elevation in the basal Akt activity in these cells.
3.3. Transient expression of the IL-2RLvA chain activates the
PI3K/Akt pathway
BafLwt and BafLvA are cell lines stably transfected with
cDNA encoding the wild type L chain or bearing a deletion
of the A-domain. To discard possible di¡erences due to clonal
variability between transfected cell lines, we also assessed both
IL-2RL-associated PI3K activity and total Akt activity in cells
transiently expressing both receptor forms. Parental cells were
electroporated with plasmids encoding cDNA for both IL-
2RLwt and BafLvA and analyzed 48 h after transfection.
PI3K activity associated with IL-2RLvA was high, and dimin-
ished following IL-2 addition (Fig. 3A). Moreover, the same
cells had higher Akt activity than those expressing the IL-
2RLwt receptor counterpart. This con¢rms that the di¡erences
between receptor-associated PI3K and total Akt activity are a
direct consequence of the deletion of the A-domain of the IL-
2RL subunit.
Fig. 1. Pharmacological inhibition of PI3K activity prevents IL-2-in-
duced proliferation of BafLwt and BafLvA cells. BafLwt or BafLvA
cells were synchronized in basal medium, then cultured in complete
medium with or without IL-2 (50 U/ml). Where indicated, cells were
preincubated with wortmannin (0.1 WM) for 1 h before IL-2 addi-
tion. Cell proliferation was determined by measuring [3H]thymidine
incorporation (see Section 2).
Fig. 2. Constitutive activation of receptor-associated PI3K/Akt ac-
tivity in BafLvA cells. (A) Synchronized BafLwt or BafLvA cells
were stimulated with IL-2 for the times indicated. IL-2RL-associated
PI3K activity was determined as described (Section 2). The ¢gure
shows [32P]PI-3-phosphate production. (B) IL-2-induced PI3K activ-
ity was measured in BafLvA immunoprecipitates following 4 or 8 h
starvation in basal medium, as described for A. (C) Synchronized
BafLwt and BafLvA cells were stimulated with IL-2 and Akt activ-
ity determined in immunoprecipitates (see Section 2).
Fig. 3. PI3K/Akt activity is increased in BaF/3 cells transiently
transfected with the A-domain deleted IL-2RL. (A) BaF/3 cells were
transiently transfected with cDNA encoding the IL-2RLvA chain.
After transfection, cells were cultured in IL-3-conditioned medium
for 24 h, synchronized in basal medium and IL-2-stimulated for the
times indicated. IL-2RL-associated PI3K activity was determined as
described. (B) IL-2RLwt or IL-2RLvA were transiently transfected
into the BaF/3 cell line. Cells were cultured in IL-3-conditioned me-
dium and synchronized in basal medium for 6 h, after which total
Akt activity was determined as described.
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3.4. A-domain deletion does not a¡ect PI3K association to the
IL-2RL subunit
Our experiments indicated that deletion of the IL-2RL A-
domain induced elevated PI3K activity associated with the IL-
2RL chain in the absence of cytokine stimulation. We there-
fore analyzed the consequence of this deletion on the basal
constitutive association of this lipid kinase with the receptor.
Using an antibody speci¢c for p85, the regulatory subunit of
PI3K, we found that A-domain deletion did not signi¢cantly
alter the level of receptor-associated p85 (Fig. 4). As a control,
the blots were reprobed with Jak1, the tyrosine kinase con-
stitutively associated with the serine-rich domain of IL-2RL.
These experiments allow us to conclude that the increased
PI3K activity associated with the receptor bearing the A-do-
main deletion is not caused by greater association of the en-
zyme with the IL-2RL chain.
3.5. A-domain deletion confers a survival advantage on
transfected cells
Activation of the PI3K/Akt pathway contributes to IL-2-
regulated survival and proliferation mechanisms [18]. We rea-
soned that if deletion of the A-domain induced higher recep-
tor-associated PI3K activity and this in turn increased basal
Akt activity, cells expressing the mutated receptor would have
a survival or proliferation advantage over cells expressing the
wild type receptor. To test this hypothesis, we generated new
clones of BaF/3 cells expressing either the wild type or the A-
deleted IL-2RL chain. The total number of clones obtained
for the IL-2RLvA mutant was 10 times greater than that
obtained for cells bearing the IL-2RLwt (Fig. 5A). Moreover,
in IL-2RLvA cDNA-transfected cells, we consistently found a
larger number of clones expressing low levels of the trans-
fected L chain, whereas in the case of transfection with the
wild type IL-2RL receptor, only cells expressing high levels of
IL-2RLwt molecules were obtained. To further demonstrate
that the IL-2R-associated PI3K activity was constitutively
higher, independently of the number of receptors expressed
on the cell surface, we determined the lipid kinase activity
in two clones expressing either high or low numbers of cell
surface IL-2RLvA. The behavior of both clones was similar,
Fig. 5. Transfection of the IL-2RLvA confers a survival/proliferative
advantage on BaF/3 cells. (A) BaF/3 cells were transfected with IL-
2RLwt or LvA chains. Clonal selection of the cells was performed
by limiting dilution; cells were cultured in complete medium with
IL-2 (50 U/ml). The number of clones expressing high or low num-
bers of cell surface IL-2RL molecules is shown. (B) Two indepen-
dent clones expressing low (3.12) or high (3.13) numbers of cell sur-
face receptors were selected and IL-2RL-associated PI3K activity
was determined as in Fig. 2.
Fig. 6. Regulation of c-myc by the PI3K/Akt pathway. (A) After
4 h starvation in basal medium, cells were preincubated with the in-
hibitor LY292002 (10 WM) or vehicle, and stimulated with IL-2 for
2 h. Cells were collected, lysed, proteins resolved by SDS^PAGE
and c-myc expression was analyzed by Western blot. (B) BafLwt
cells were co-transfected with a c-myc promoter-driven luciferase
gene and plasmids encoding a constitutive active form of PI3K
(p110-CAAX) or wild type Akt. After transfection, cells were cul-
tured in IL-3-conditioned medium for 24 h, followed by incubation
in basal medium for an additional 8 h; luciferase activity was then
determined. (C) BafLwt cells were transfected with the c-myc pro-
moter-driven luciferase gene and cultured in complete medium with
or without IL-2 (50 U/ml) for 18 h. The inhibitor LY292002 (LY,
10 WM) was added where indicated.
Fig. 4. Deletion of the A-domain has no e¡ect on PI3K association
to the IL-2RL. (A) BafLwt or BafLvA cells were synchronized in
basal medium for 6 h, lysed, and the PI3K associated to the IL-
2RL chain determined by Western blot analysis of IL-2RL immuno-
precipitates using an antibody speci¢c for the PI3K regulatory sub-
unit p85. 10% of the total cell lysates were also analyzed. (B) The
same membranes as in A were reprobed for Jak1 association using
a speci¢c antibody.
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and in both cases IL-2 addition resulted in a decrease in the
associated PI3K activity (Fig. 5B).
3.6. Involvement of PI3K-regulated pathways in c-myc
induction
Activation of the PI3K/Akt pathway by growth factors has
been shown to regulate several signals required for cell pro-
liferation. Addition of IL-2 to lymphocytes results in the rapid
expression of c-myc, and induction of this proto-oncogene is
essential for IL-2-induced cell proliferation [28]. Pharmacolog-
ical inhibition of PI3K prevents the induction of c-myc that
follows IL-2 addition to both IL-2RLwt and IL-2RLvA cells
(Fig. 6A). To further evaluate the role of the PI3K/Akt
pathway on c-myc regulation, we examined the e¡ect of
constitutive activation of this pathway on the transcriptional
regulation of the c-myc promoter. Overexpression of 3P phos-
phorylated derivatives of PI or Akt overexpression are both
su⁄cient to induce a detectable increase in the transcriptional
activity of the c-myc promoter (Fig. 6B). Treatment of the
cells with a pharmacological inhibitor of PI3K prevents IL-2
induction of the c-myc promoter (Fig. 6C). Taken together,
these data demonstrate that PI3K regulation by IL-2 is essen-
tial for c-myc induction, con¢rming the importance of this
lipid kinase in the control of proliferation.
4. Discussion
Activation of PI3K has been implicated in two important
functions for IL-2, cell proliferation and prevention of apo-
ptosis [14,18,19]. The lack of IL-2-induced Akt activation in
cells transfected with the IL-2RLA deletion mutant suggested,
however, that regulation of the PI3K/Akt pathway by IL-2 is
not required for proliferation [16]. The detailed analysis, pre-
sented here, of the IL-2 regulation of PI3K-derived signals in
BafLvA cells, has allowed re-evaluation of the role of this
pathway in IL-2-mediated proliferation. Deletion of the IL-
2RL chain A-domain induces a concomitant increase in the
PI3K activity constitutively associated to this molecule. This
basal activation of the PI3K/Akt pathway is important for IL-
2-induced cell proliferation, since inhibition of PI3K activity,
either by addition of pharmacological inhibitors or following
transfection of a construct with dominant negative properties
(data not shown), has a profound e¡ect on cell proliferation
in response to this cytokine. These data con¢rm our previous
observation [17] that an early increase in 3P phosphorylated PI
derivatives is necessary, but not su⁄cient, for IL-2-induced
proliferation. Moreover, we demonstrate downregulation of
receptor-associated PI3K activity in response to IL-2 addition,
con¢rming that not only the activation, but also the down-
regulation of PI3K activity by IL-2-induced signals are im-
portant for cytokine-regulated cell proliferation. These data
explain the lack of activation of the Akt pathway by IL-2
previously described in BafLvA cells [16].
Our experiments demonstrate constitutive association of
PI3K activity to the L subunit of the IL-2R. These results
concur with recent studies by Migone et al., who showed
that p85 associates to Jak1, which is in turn associated to
the S-rich domain of IL-2RL [16]. In those studies, the au-
thors elegantly demonstrated that the A-domain was required
for a more e¡ective association of p85 to the receptor, but the
activity of the p85/p110 heterodimer was not investigated. The
regulatory subunit of PI3K has been shown to negatively
modulate the catalytic activity of p110 both in vitro and in
vivo [20,21]. The activity of p85/p110 dimers is increased when
the SH2 domains of p85 bind to phosphorylated residues in
the proteins that contain the appropriate sequence motifs [22].
This suggests that the increased activity of the heterodimer
when bound to phosphoproteins is not a true activation, but
rather a disinhibition of the p85/p110 heterodimer. p85/p110
dimer activity may also be a¡ected by other mechanisms, such
as binding to GTP-bound ras and CDC42 [23,24], SH3 do-
main from Src family kinases [25] or proline-rich proteins that
bind to the p85 SH3 domain [26]. Although not examined in
detail, it would be interesting to determine whether activation
of p85/p110 dimers in these cases also re£ects a transition
between inhibited and disinhibited states. Our experiments
suggest that deletion of the A-rich domain of the IL-2RL
chain induces disinhibition of the e¡ect of the regulatory sub-
unit on the p110 catalytic activity by a mechanism that re-
mains to be de¢ned.
We have shown that while activity of receptor-associated
PI3K activity is enhanced in the absence of IL-2, addition
of this cytokine to BafLvA cells results in rapid downregula-
tion of associated PI3K activity. Activation of PI3K in re-
sponse to IL-2, as is the case for the majority of growth factor
receptors, is rapid and transient, suggesting rapid downregu-
lation of this activity following those signals responsible for
PI3K association/activation. Although the mechanisms under-
lying PI3K activation in response to growth factors have been
reviewed extensively, few data in the literature have addressed
the downregulation of this activity. The recent discovery of
the profound e¡ect on cell transformation caused by muta-
tions in the lipid phosphatase PTEN underlines the impor-
tance of a regulated balance, not only in the production but
also in the degradation of 3-phosphorylated lipids for correct
cell homeostasis [27]. This IL-2RL chain mutation represents
an invaluable model to study the mechanisms by which IL-2
downregulates PI3K activity.
Activation of PI3K/Akt by IL-2 has been related to the
anti-apoptotic e¡ects of this cytokine [18]. Our experiments
demonstrate that inhibition of PI3K prevents IL-2-regulated
proliferation without a¡ecting IL-2-induced survival, con¢rm-
ing our previous observation of the existence of alternative
mechanisms of IL-2 protection from apoptosis [17]. IL-2-
mediated expression of the cell cycle regulator E2F has been
shown to be mediated by PI3K activity, suggesting that this
pathway serves as a link between the IL-2R and the cell cycle
machinery [14]. Here we show that IL-2-mediated PI3K acti-
vation can also regulate c-myc expression, suggesting the ex-
istence of multiple cell cycle control mechanisms regulated by
IL-2R-triggered 3P phosphorylated lipid products. Induction
of c-myc has been demonstrated to be essential for IL-2-in-
duced proliferation [28], nevertheless very little is known
about the early signals that regulate IL-2-induced c-myc ex-
pression. Our experiments demonstrate for the ¢rst time a
direct correlation between PI3K and c-myc induction.
The role of the A-domain deletion has recently been eval-
uated in primary lymphocyte populations through generation
of mice expressing the IL-2RLA transgene on an IL-2RL null
background [29]. T cells expressing the IL-2RLvA mutant
exhibited increased IL-2-mediated proliferation, indicating
that the lack of this domain results in enhanced proliferation
of primary T cells. This enhancement was accompanied by the
prolonged phosphorylation of IL-2RL, suggesting that dele-
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tion of the A-region results in the loss of signals involved in
negative regulation. Examination of PI3K activity in these
cells should provide further evidence of the role of these path-
ways in IL-2-mediated cell proliferation.
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